Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sigma-Aldrich

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Merck takes novel immuno-oncology drug into clinical trials

Potential to offer alternative to anti-PD-1/anti-PDL1 immunotherapies 

- PMLiVE

Merck KGaA appoints Isabel De Paoli as communications head

She will replace Walter Huber, who retires inMarch 2016

- PMLiVE

Horizon launches $3bn hostile bid for Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

A bright future for OTC and Merck Consumer Health

It’s an exciting time for the OTC sector. Consumers have never been more interested in wellbeing and, of course, avoiding illness. This is driving change, and quickly. The market is...

- PMLiVE

Receptos rejected AZ takeover bid, say sources

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

Perrigo warming to Mylan – at the right price

Perrigo has already rejected three prior bids

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links